Home › Funds › Soleus Capital Management, L.P. › KNSA

Soleus Capital Management, L.P. position in KNSA

KINIKSA PHARMACEUTICALS INTL · Health Care

Soleus Capital Management, L.P. reported holding 246,353 shares of KNSA (KINIKSA PHARMACEUTICALS INTL) in its Q2 2026 13F filing — a position valued at US$15.8M, representing 0.54% of its reported portfolio and ranking #48 among its reported holdings. Soleus Capital Management, L.P. has disclosed KNSA holdings in 9 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)246.35K sh
Reported value held$15.75M
Portfolio Weight0.54%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s KNSA position evolved

Soleus Capital Management, L.P. first disclosed a stake in KNSA in Q3 2023 at 157,349 shares (US$2.7M). The position peaked in Q1 2026 at 521,353 shares, worth US$25.1M. Across 9 filings, Soleus Capital Management, L.P. increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 246,353 shares valued at US$15.8M — a reduction of -275,000 shares quarter over quarter.. Notable position changes include a 51% increase in Q3 2024 (shares fell 21% over the following quarter), a 291% increase in Q4 2025 (shares rose 17% over the following quarter), a 53% trim in Q2 2026 (shares rose 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 157.35K $2.73M New
Q2 2024 200.00K $3.73M New
Q3 2024 302.50K $7.56M Add
Q1 2025 469.50K $10.43M New
Q2 2025 254.69K $7.05M Reduce
Q3 2025 150.00K $5.82M Reduce
Q4 2025 587.00K $24.21M Add
Q1 2026 521.35K $25.10M Reduce
Q2 2026 246.35K $15.75M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KNSA and 13F data

KNSA (KINIKSA PHARMACEUTICALS INTL) is a Health Care company. 48 other funds we track also report a position in KNSA — the largest reported positions include Rubric Capital Management LP (US$255.8M), BAKER BROS. ADVISORS LP (US$181.3M), TANG CAPITAL MANAGEMENT LLC (US$144.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KNSA

All KNSA fund holders →

FAQ

How long has Soleus Capital Management, L.P. held KNSA?

Soleus Capital Management, L.P. has disclosed KNSA holdings in 9 of the last 12 reported quarters, going back to Q3 2023.

What is Soleus Capital Management, L.P.'s current position in KNSA?

As of Q2 2026, Soleus Capital Management, L.P. holds 246.35K shares of KNSA (KINIKSA PHARMACEUTICALS INTL), valued at $15.75M, representing 0.54% of its reported portfolio and ranking #48.

Has Soleus Capital Management, L.P. been buying or selling KNSA?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. reduced its position in KNSA. The position peaked in Q1 2026 at 521.35K shares.

Which other funds hold KNSA?

Other major institutional holders of KNSA include Rubric Capital Management LP, BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.